190 related articles for article (PubMed ID: 35676636)
21. Effectiveness and Safety of CGRP-mAbs in Menstrual-Related Migraine: A Real-World Experience.
Silvestro M; Orologio I; Bonavita S; Scotto di Clemente F; Fasano C; Tessitore A; Tedeschi G; Russo A
Pain Ther; 2021 Dec; 10(2):1203-1214. PubMed ID: 34106431
[TBL] [Abstract][Full Text] [Related]
22. How much do calcitonin gene-related peptide monoclonal antibodies improve the quality of life in migraine? A patient's perspective.
Torres-Ferrus M; Alpuente A; Pozo-Rosich P
Curr Opin Neurol; 2019 Jun; 32(3):395-404. PubMed ID: 30950844
[TBL] [Abstract][Full Text] [Related]
23. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
24. Experts and national consultants' recommendations regarding management of patients treated for migraine with comorbid depression. Diagnosis. Therapeutic strategies. Part 2.
Stepień A; Słowik A; Domitrz I; Kozubski W; Rejdak K; Rożniecki J; Woroń J; Wachowska K; Gałecki P
Psychiatr Pol; 2022 Aug; 56(4):711-728. PubMed ID: 37074825
[TBL] [Abstract][Full Text] [Related]
25. Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab.
Buse DC; Lipton RB; Hallström Y; Reuter U; Tepper SJ; Zhang F; Sapra S; Picard H; Mikol DD; Lenz RA
Cephalalgia; 2018 Sep; 38(10):1622-1631. PubMed ID: 30086681
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments.
Kuruppu DK; Tobin J; Dong Y; Aurora SK; Yunes-Medina L; Green AL
BMC Neurol; 2021 Apr; 21(1):175. PubMed ID: 33892641
[TBL] [Abstract][Full Text] [Related]
27. Calcitonin gene-related peptide induced migraine attacks in patients with and without familial aggregation of migraine.
Guo S; Christensen AF; Liu ML; Janjooa BN; Olesen J; Ashina M
Cephalalgia; 2017 Feb; 37(2):114-124. PubMed ID: 26994300
[TBL] [Abstract][Full Text] [Related]
28. Refractory migraine profile in CGRP-monoclonal antibodies scenario.
Silvestro M; Tessitore A; Scotto di Clemente F; Battista G; Tedeschi G; Russo A
Acta Neurol Scand; 2021 Sep; 144(3):325-333. PubMed ID: 34019304
[TBL] [Abstract][Full Text] [Related]
29. United States Patients' Perspective of Living With Migraine: Country-Specific Results From the Global "My Migraine Voice" Survey.
Gibbs SN; Shah S; Deshpande CG; Bensink ME; Broder MS; Dumas PK; Buse DC; Vo P; Schwedt TJ
Headache; 2020 Jul; 60(7):1351-1364. PubMed ID: 32369201
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study.
Jakate A; Blumenfeld AM; Boinpally R; Butler M; Borbridge L; Contreras-De Lama J; McGeeney D; Periclou A; Lipton RB
Headache; 2021 Apr; 61(4):642-652. PubMed ID: 33818780
[TBL] [Abstract][Full Text] [Related]
31. The not so hidden impact of interictal burden in migraine: A narrative review.
Vincent M; Viktrup L; Nicholson RA; Ossipov MH; Vargas BB
Front Neurol; 2022; 13():1032103. PubMed ID: 36408525
[TBL] [Abstract][Full Text] [Related]
32. [Application of CGRP-Related Monoclonal Antibodies in Migraine Management].
Shibata M
Brain Nerve; 2021 Apr; 73(4):327-337. PubMed ID: 33824220
[TBL] [Abstract][Full Text] [Related]
33. Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience.
Raffaelli B; Terhart M; Mecklenburg J; Neeb L; Overeem LH; Siebert A; Steinicke M; Reuter U
J Headache Pain; 2022 Mar; 23(1):40. PubMed ID: 35350990
[TBL] [Abstract][Full Text] [Related]
34. Real-world effectiveness and satisfaction with intravenous eptinezumab treatment in patients with chronic migraine: REVIEW, an observational, multi-site, US-based study.
Argoff C; Herzog SP; Smith RM; Kotak SV; Sopina L; Saltarska Y; Soni-Brahmbhatt S; Khan FA
J Headache Pain; 2024 Apr; 25(1):65. PubMed ID: 38664605
[TBL] [Abstract][Full Text] [Related]
35. Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: A meta analysis.
Hong P; Wu X; Liu Y
Clin Neurol Neurosurg; 2017 Mar; 154():74-78. PubMed ID: 28129635
[TBL] [Abstract][Full Text] [Related]
36. Anti-calcitonin gene-related peptide monoclonal antibodies for neuropathic pain in patients with migraine headache.
Kang SA; Govindarajan R
Muscle Nerve; 2021 Apr; 63(4):563-567. PubMed ID: 33347632
[TBL] [Abstract][Full Text] [Related]
37. Impact of the COVID-19 pandemic on people living with migraine: Results of the MiCOAS qualitative study.
Buse DC; Gerstein MT; Houts CR; McGinley JS; Uzumcu AA; McCarrier KP; Cooke A; Touba NM; Nishida TK; Wirth RJ; Lipton RB
Headache; 2022 Mar; 62(3):284-293. PubMed ID: 35294046
[TBL] [Abstract][Full Text] [Related]
38. Calcitonin gene-related peptide in migraine: from pathophysiology to treatment.
Santos-Lasaosa S; Belvís R; Cuadrado ML; Díaz-Insa S; Gago-Veiga A; Guerrero-Peral AL; Huerta M; Irimia P; Láinez JM; Latorre G; Leira R; Pascual J; Porta-Etessam J; Sánchez Del Río M; Viguera J; Pozo-Rosich P
Neurologia (Engl Ed); 2022 Jun; 37(5):390-402. PubMed ID: 35672126
[TBL] [Abstract][Full Text] [Related]
39. Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.
Scheffler A; Messel O; Wurthmann S; Nsaka M; Kleinschnitz C; Glas M; Naegel S; Holle D
J Headache Pain; 2020 Jul; 21(1):84. PubMed ID: 32620151
[TBL] [Abstract][Full Text] [Related]
40. Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(-receptor) antibodies.
Terhart M; Mecklenburg J; Neeb L; Overeem LH; Siebert A; Steinicke M; Raffaelli B; Reuter U
J Headache Pain; 2021 Dec; 22(1):158. PubMed ID: 34972502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
